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INTRODUCTION

TABLES 1-3

There are numerous studies discussing thromboprophylaxis after total joint arthroplasty
(TJA), which have varying conclusions. The patient inclusion criteria may be different for
each study, which may lead to selection bias and misrepresenting data.

Table 1. Patient Demographics and study information of funded vs. non-funded studies.

The purpose of this study was to investigate if industry funding impacted patient
demographics and overall reported outcomes of studies analyzing venous thromboembolism
(VTE) prevention after TJA.

MATERIALS & METHODS

Electronic searches were completed for Ovid, PubMed, and Embase. Studies were included if:
(1)
published in the English language between 2000 and 2016
(2)
including patients undergoing total hip arthroplasty (THA) or total knee arthroplasty
(TKA)
(3)
evaluating prevention and control of postoperative VTE with at least one of the
following thromboprophylactic agents: aspirin, enoxaparin, deltaparin, dabigatran,
apixaban, rivaroxaban, dabigatran, ximelagatran, fondaparinux or coumadin. Data was
extracted and analyzed via mixed-effect logistic regression.
Records identified
by electronic
literature search
(n=995)

Funded Studies
(n=29)

Non-funded Studies
(n=28)

p-value

Conflict of Interest

23

9

0.000

Excluded Revisions
Retrospective
Male (%)
Age (mean)
BMI (mean)

15
4
39.41%
66.7
29.0

12
14
31.09%
66.7
28.8

0.512
0.013
0.019
1.000
0.729

Table 2. Number of funded and non-funded studies including each drug category.

Funded
Studies

Non-funded
Studies

Aspirin +/- foot
pump
Enoxaparin

4
18

8
18

Foot pump only

1

3

Oral
anticoagulants*

20

11

5
7

6
9

LMWH&

Other
Warfarin

Records after
duplicates
removed (n=766)

RESULTS

DISCUSSION

Industry-funded studies reported less PE, major bleeding, and mortality compared
to non-funded studies. There were no differences in patient demographics or drug
effect.
It is important to investigate the underlining reason how funded studies are reporting
fewer poor outcomes than non-funded studies. In addition, our data suggests careful
examination of data from funded studies when applying results to a clinical basis.

*: İncluding dabigatran, apixaban, rivaroxaban, ximelgatran.
&: İncluding fondaparinux and daltaparin.

Table 3. Outcomes of funded vs. non-funded studies.
Records screened
(n=766)

Full Texts
assessed for
eligibility
(n=105)
Studies included
in analysis (n=57)

Records excluded after
screening titles and
abstracts (n=661)
Full Texts excluded (n=48)
-No sole chemoprophylactic agent (n=20)
-Not original studies (n=10)
-Not available in full texts (n=3)
-Did not report patient demographics (n=8)
-Did not report adverse outcomes (n=7)

Figure 1. Screening and selection for this systematic review.

Funded Studies

Future studies should further investigate patient demographics, study design, and
additional forms of bias that may arise in orthopedic research.

Non-funded Studies

p-value

PE % (95% CI)

0.29% (0.19 - 0.42)

0.72% (0.47 - 1.12)

0.001

DVT % (95% CI)

3.78% (2.09 - 6.72)

3.27% (1.84-5.73)

0.728

Major Bleeding % (95%
CI)
0.75% (0.52 - 1.11)

1.4% (0.84 - 2.33)

0.046

Mortality % (95% CI)

0.38% (0.25 -0 .57)

0.000

0.12% (0.09 - 0.16)

There were 57 studies included in this systematic review; 29 studies were industry
funded and 28 were non-funded
•
There was no overall drug effect between reporting outcomes, patient
demographics, and level of funding.
•
There were no significant differences between patient age, BMI, or revision
exclusions between funded and non-funded studies.
•
However, funded studies reported less pulmonary embolisms (PE) (0.29%,
95% CI 0.19-0.42) compared to non-funded studies (0.72%, 95% CI; 0.47-1.12)
(p=0.001).
•
Funded studies also reported fewer events of major bleeding (0.75%, 95% CI;
0.52-1.11) than non-funded studies (1.4%, 95% CI; 0.84-2.33) (p=0.046).
•
Funded studies also reported significantly less 90-day mortality (0.12% (95%
CI; 0.09-0.16) than non-funded studies (0.38%, 95% CI; 0.25-0.57) (p=0.000).
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